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Abstract 
Acetylcysteine has been used as a treatment for paracetamol overdose as a 20.25 
or 21 h infusion for nearly 40 years. These regimens give 50% of the dose in the 
first 15 min or 1 h, and are associated with high rates of adverse reactions. 
A randomised controlled trial has demonstrated that a shorter (12 h) and 
simpler (2 infusions) acetylcysteine regimen using a slower initial infusion rate 
produces lower rates of adverse events than the original 20.25h regimen. 
However this study was not sufficiently large to show therapeutic equivalence as 
a hepatoprotective therapy in paracetamol overdose. Two further studies are 
now reported, which also suggest lower rates of adverse reactions with lower 
initial rates of acetylcysteine administration. These modified regimens can now 
be accepted as better tolerated, but it is unlikely that a randomised study of 
sufficient size to demonstrate non-inferiority of any novel regimen this would 
ever be funded. Against this background we suggest what can be done to 
establish the efficacy of these less toxic and potentially shorter alternative 
acetylcysteine regimens and to establish them into routine clinical use. 
 
Background 
 
Intravenous acetylcysteine has been used widely to treat paracetamol 
(acetaminophen) poisoning for almost 40 years. (1, 2)  An oral regimen is also 
effective and was previously the antidote of choice in the United States (3), but 
an appropriate intravenous preparation became available in 2004 and use of this 
is now much more common than oral therapy.(4) 
 
The original dosing regimen for intravenous acetylcysteine, developed by 
Prescott and colleagues in Edinburgh (referred to here as the Prescott regimen), 
was empirically based and intended to deliver a large dose of antidote rapidly. It 
involved half the total dose of acetylcysteine (150 mg/kg) being given over 15 
minutes with the remainder delivered over a further 20 hours (50 mg/kg over 4 
h then 100 mg/kg over 16 h). While this regimen is undoubtedly effective and 
has saved countless lives, it has four major disadvantages: the high rate of 
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adverse reactions, the complexity of the infusion regimen, the risk or medication 
error and the prolonged duration of treatment. 
 
Adverse reactions are common, especially nausea and vomiting and so-called 
anaphylactoid reactions.  Risks of these were initially considered reasonable 
compared to those of untreated paracetamol poisoning.  These anaphylactoid 
reactions, sometimes termed non allergic anaphylactic reactions (NAAR) are not 
allergic in nature, but arise from dose related stimulation of histamine release. 
They occur most commonly during, or soon after, the initial infusion, when 
acetylcysteine concentrations are at their highest.  Importantly, they are more 
common in patients with lower paracetamol concentrations who have lower risk 
of paracetamol-induced hepatotoxicity (5-7). 
 
In Canada, USA and subsequently in Australia, a one-hour initial infusion was 
adopted with the aim of reducing peak acetylcysteine concentrations and 
causing fewer adverse reactions.  A randomised clinical trial in Australia, 
however, did not demonstrate a statistical difference in ADRs between a one-
hour and a 15-minute initial infusion, although this trial was underpowered to 
demonstrate small clinically relevant differences. (8) Nevertheless, an initial 1 
hour infusion was incorporated into the license for acetylcysteine in the UK in 
2012 by the Medicines and Healthcare Products Regulatory Agency.(9) However 
comparing data collected before and after the change we found no reduction in 
the rates of medication use for treating adverse reactions. The only difference 
was that ADRs were delayed in those receiving the slower infusion.(7) 
 
The complexity of the intravenous regimen, requiring 3 separate infusions, is a 
problem because this requires staff time to manage each infusion. Importantly 
dose calculation errors are common, in part arising from the complexity of the 
regimen.  These may result in substantial overdose, and most deaths associated 
with acetylcysteine have occurred under these circumstances. (10) The duration 
of infusion (20.25 or 21 hours) is an important disadvantage because it leads to 
significant hospital bed occupancy that may not be necessary in all patients, 
especially those at lower risk. Given the pressures on hospital emergency 
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departments, enhancing tools to safely discharge patients earlier than is 
currently possible should be a clear research priority across all poisonings.  
 
Modified intravenous acetylcysteine regimens 
 
There has recently been increasing interest in making modifications to the 
intravenous acetylcysteine protocol. This is primarily to reduce adverse 
reactions, but also to simplify and shorten the regimen. However there are 
challenges in demonstrating that changes made are of clinical benefit. Ideally, 
new and current regimens would be compared using an adequately powered and 
well-designed randomised controlled trial.   Such studies are difficult to organise 
and perform: even those adequately powered to demonstrate differences in 
adverse reaction rates require hundreds of participants. Ensuring that efficacy is 
maintained is especially difficult because adverse hepatic outcomes are rare with 
the currently used acetylcysteine regimens and thus clinical trials need to 
involve thousands of patients to demonstrate non-inferiority. Without evidence 
of comparative efficacy, however, regulatory authorities are unlikely to license 
novel acetylcysteine regimens., 
 
Although challenging, we have demonstrated that randomised controlled trials 
can be done successfully. We compared a novel 12 h regimen employing 2 
sequential acetylcysteine infusions (100 mg/kg over 2 h, 200 mg/kg over 10h), 
the ‘SNAP’ regimen, with the standard Prescott approach.(11) This new method 
was designed to provide lower initial paracetamol concentrations with the aim 
of reducing adverse reactions and also to be shorter, potentially allowing earlier 
discharge from hospital for lower risk patients.(12)  
 
This study was designed as a 4 arm factorial study, with the effects of 
ondansetron on rates of vomiting also studied.  Predefined endpoints were used, 
based on a formal statistical calculation of the likely impact of additional 
antiemetic therapy, with data collected at predefined time points. Using this 
design, we showed a marked reduction in the frequency of both vomiting 
(adjusted odds ratio 0·26, 97·5% CI 0·13–0·52; p<0·0001) and anaphylactoid 
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reactions which required either treatment interruption or specific therapy 
(adjusted common odds ratio 0·23, 97·5% CI 0·12–0·43; p<0·0001) with the new 
regimen.(11) 
 
It had been our original intention to obtain funding for a non-inferiority efficacy 
study, but funding bodies were unwilling to underwrite the size of trial we 
calculated was necessary to achieve this objective. Thus, the study we published 
was underpowered to assess comparative efficacy using standard criteria. In an 
attempt to address this we used an approach to hepatic toxicity not generally 
applied by others working in the area of paracetamol poisoning. This was to 
consider much smaller rises in ALT than the 1000 IU/L traditionally applied. 
Even doing this and using a novel microRNA biomarker miR-122 we could not 
separate the conventional and modified 12 h acetylcysteine regimens with 
respect to prevention of liver injury.  
 
Although randomised controlled trials remain the gold standard, valuable 
information may be obtained from non-randomised studies, for example 
comparing data collected with a new regimen with historical data collected in 
the same unit or published in the literature. It is challenging, however, to ensure 
that comparisons made are valid and without confounding or bias.  This is 
especially true for assessing adverse reactions, where symptoms may be 
subjective and different methodologies provide substantially different estimates 
of incidence.  Several studies have used chart review, but because adverse 
reactions are often not recorded in medical records, these often detect only the 
more severe reactions. For example, when evaluated prospectively in a clinical 
trial setting, anaphylactoid reactions occurred in about 30% of patients treated 
with the original acetylcysteine regimen. If minor symptoms self-reported by 
patients are included the rate of these reactions rises to 70%.(11) In contrast, 
while using a chart review approach in the same unit anaphylactoid reactions 
were recorded in only about 10%.(7) 
 
In this context we were interested to review the two non-randomised studies 
published in this issue of the journal. (13, 14) As in our study, both of the 
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regimens studied used a reduced initial infusion rate of acetylcysteine. Both 
combined the total acetylcysteine dose in the first two bags of the Prescott 
regimen (200 mg per kilogram) into a single infusion and administered it over at 
least four hours, but unlike with our regimen, the total duration of acetylcysteine 
was not substantially reduced. 
 
Wong and Graudins studied 210 patients using a 20 hour regimen consisting of 
200 mg/kg acetylcysteine over four hours followed by 100 mg/kg over 16 
hours.(13) They used chart review to assess adverse events, compared to 389 
historical controls.  While this may underestimate true adverse reaction rates, 
the comparison is valid if identical methodology is used. There was a significant 
reduction in anaphylactoid responses [10 v 4.3% OR 2.5 (95%CI 1.1-5.8) p=0.02].  
Interestingly, in contrast to us, their longer, larger initial infusion showed no 
difference in GI adverse effects [vomiting 39% conventional; 41% 4 h initial 
infusion]. No difference in efficacy was detected, but the study, like ours, was not 
adequately powered for this. 
 
Isbister and colleagues (14) used a variable infusion rate, starting acetylcysteine 
as soon as possible after presentation and tailoring the  duration of the initial 
infusion from 4 to 9h so that the loading dose would be completed within 11 
hours of the overdose. This has the advantage of reducing the infusion rate, and 
thus incidence of adverse reactions, for many patients. It also ensures that the 
initial acetylcysteine infusion is completed within a time frame thought to be 
associated with optimum efficacy.  However this regimen suffers from 2 major 
disadvantages. Firstly, treatment is started before results of paracetamol 
concentrations are known, meaning that many patients receive treatment that 
subsequent blood results demonstrate is not needed.  Indeed, acetylcysteine was 
subsequently stopped in 420 of the 654 patients studied as they were deemed to 
be below the nomogram treatment line. Secondly, the variable duration of the 
initial infusion is complex and likely to be difficult to deliver consistently in non-
specialist units.  The results demonstrated a lower rate of adverse reactions 
compared to other published series, but the validity of this comparison is 
questionable as methodology may vary between studies. 
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The results of both of these studies confirm those of our randomised controlled 
study, demonstrating that reduction in the initial acetylcysteine infusion dose 
rate to 50mg/kg/hr reduces the incidence of adverse reactions. However, we 
believe that new acetylcysteine regimens should also be shorter than currently 
used, to allow safe early discharge of low risk patients. In our trial population 
96% had paracetamol concentrations below 20 mg/L at the end of the 12 h 
acetylcysteine regimen and no patient who had a normal ALT at this point went 
on to develop significant liver injury. It is therefore likely that patients with a 
normal ALT at that time could be discharged safely, freeing up many acute 
hospital beds.  However, data collection is needed from a much larger number of 
patients to confirm this, and this needs to involve patients excluded from our 
clinical trial such as those ingesting staggered overdoses and those presenting 
more than 24 hours after overdose.  
 
Acetylcysteine concentrations with different regimens 
 
Giving a fixed dose of a drug in different ways will inevitably result in different 
plasma concentration profiles. Chiew and colleagues have recently published a 
detailed analysis of a variety of regimens using a 3-compartment 
pharmacokinetic model. They clearly show that the modified 2 stage regimens, 
using either our 12h (2h 100mg/kg + 10h 200mg/kg), or the 20 h (4 h 200mg/kg 
+ 16 h 100mg/kg), result in different acetylcysteine concentrations. Thus 
modelling indicates that, inevitably, all slower regimens result in lower 
concentrations over the first hour than the conventional regimen. Our regimen, 
where acetylcysteine is discontinued after 12 h, results in lower acetylcysteine 
concentrations at 20 h post infusion commencement than the 20 h infusions 
used by Wong and Graudins or Isbister et al.(13, 14) For this reason, when our 
regimen is used a further 10h acetylcysteine infusion is recommended for high 
risk patients, such as those with persisting paracetamol concentrations or 
evolving liver function abnormalities at 12h. Few patients, however, require 
additional therapy after the initial 12 h protocol. In our study only 8 of 110 
patients on the modified regimen had a 50% increase in ALT at 12 h, and 96% 
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had a paracetamol concentration <20mg/L. Only 2 of these had an ALT of >1000 
at 20.25 h, and no patient developed severe hepatotoxicity who was not 
identified as abnormal at 12 h using our criteria.(11) These rates were similar to 
the standard 20.25 h regimen. We believe this finding is reassuring, but 
recognise the limitations of our study in terms of size and patient group. 
 
The way forward 
 
There is now strong and consistent evidence that reducing the initial infusion 
rate of acetylcysteine reduces the rate of adverse reactions, and we probably 
don’t need further evidence of that. The challenge going forwards is to 
demonstrate that newer regimens are as effective as the original in preventing 
serious hepatotoxicity. Since serious hepatotoxicity is uncommon in those 
treated with currently licensed regimens, very large patient numbers are needed, 
and perhaps no funding agency can underwrite a formal controlled trial of an 
appropriate size. In this situation a pragmatic approach is needed: it is 
reasonable for clinical units to take individual decisions on which evidence-
based treatment regimen to adopt, but they should collect robust data 
prospectively using consistent methods that are comparable across units and can 
be pooled centrally in an anonymised format. This approach is being adopted by 
several specialist Clinical Toxicology Units in the UK, which are switching to the 
‘SNAP’ 12h acetylcysteine protocol but with careful audit of liver injury 
outcomes. While there are difficulties comparing rates of adverse reaction 
between different centres and patient cohorts, such data are now less important 
as lower adverse reaction rates are now established. To demonstrate that 
efficacy is maintained, objective data less subject to possible bias is needed, such 
as results of liver function tests. It might require several thousand patients in 
each arm to be confident of non-inferiority compared to historic data using an 
ALT 1000 IU/L cut off, so it might be prudent to also collect all ALT data in order 
to study increases of lower magnitude, as we reported, since this is not readily 
available in historic data. In addition, samples for novel biomarkers may also 
assist in helping to clarify efficacy and facilitate early discharge at the end of 12h 
treatment (15).  
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There now seems to be an opportunity for the academic organizations that 
sponsor this journal to take a clear lead on this issue internationally to provide 
independent peer review and support for proposed new regimens. This would 
facilitate their wider adoption in appropriate patient groups, and support the 
rapid collection of consistent clinical outcome data for patients treated for 
paracetamol overdose. Collection of such data from large numbers of patients is 
now essential for the widespread adoption of improved acetylcysteine infusion 
regimens. 
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